 "dr reddy's laboratory , dr reddy , drl pharma sector")
Dr Reddy's Laboratories on Tuesday said it has launched a first-in-class generic medication for chronic constipation in the country.
The drug firm has launched Linaclotide, a first-in-class guanylate cyclase-C (GC-C), under the brand name Colozo.
Linaclotide is a USFDA-approved medication indicated for adults suffering from chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C) in adults, and functional constipation (FC) in paediatric patients aged 6 to 17 years.
"The launch of Colozo marks a significant step in our gastrointestinal segment in India and adds to our list of novel and first-in-class drugs after the launch of BixiBat in India last year," Dr Reddy's CEO Branded Markets (India and Emerging Markets) MV Ramana said in a statement.
With Colozo, the company continues to strengthen its commitment to deliver advanced therapies that meaningfully improve everyday patient care, in keeping with the goal to serve 1.5 bn patients by 2030, he added.
Dr Reddy's shares on Tuesday ended 1.65 per cent down at Rs 1,263.35 apiece on the BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
 "Adani Green Energy solar project, 7 GW solar power project, Andhra Pradesh solar energy, Azure Power PPA transfer, SECI solar projects, CERC solar ruling, solar power regulatory approval, Adani Green Energy SECI deal, 2.3 GW PPA Adani, solar energy I")
 "The aspirations of a young India and increased income levels have encouraged companies to consider mergers and acquisitions (M&A) to keep up with demand. In a world where consumer preferences change dramatically, M&As provide companies the means to r")
 "Perplexity")
 "flights, planes")
 "Just a day ahead of the hurriedly called Vodafone Idea (Vi) meeting meant to soothe the nerves of investors amid the company's sliding stock price and a negative narrative around it, the telco announced a $3.6-billion (Rs 30,000 crore) deal with glob")
